Dr. Parker on the Role of Radiotherapy in Newly Diagnosed Prostate Cancer

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

Results from the STAMPEDE trial presented at the 2018 ESMO Congress showed that men with low metastatic disease burden who received radiotherapy plus standard of care had a 32% improvement in overall survival (OS) compared with men who received standard of care treatment alone.

In the prespecified subgroup analysis, radiotherapy to the prostate improved OS by 32% in the 819 men with a low burden of metastatic disease (HR 0.68, 95% CI 0.52-0.90). The absolute improvement in OS in this group at 3 years was 81%. Radiotherapy conferred no survival benefit in the men with a high metastatic disease burden, though.